BrightGene Bio-medical Technology(SH:688166) GLP1减重宝典·2025-10-20 09:21Group 1 - The core point of the article is that Borui Pharmaceutical has decided to terminate its plan for a specific issuance of A-shares for 2024 due to a comprehensive assessment of the current market environment and its own operational status [4][6] - The company had previously planned to raise 500 million yuan through this issuance, which was to be fully subscribed by its actual controller, Yuan Jiandong [4] - The initial plan was approved in May 2024, but there was no substantial progress over the year, leading to multiple revisions of the issuance plan before the company voluntarily withdrew its application [4] Group 2 - Borui Pharmaceutical is planning to issue H-shares and list on the Hong Kong Stock Exchange in 2025 to accelerate its internationalization and enhance its capital strength [6] - The company has appointed Ernst & Young as the auditing firm for this upcoming Hong Kong listing [6] - Established for over 20 years, Borui Pharmaceutical's product portfolio includes innovative drugs across various therapeutic areas, including metabolism, antiviral, antifungal, immunosuppressive, respiratory, and oncology [6] Group 3 - As of now, Borui Pharmaceutical has a market capitalization of approximately 24.5 billion yuan and has completed three rounds of financing since its IPO in November 2019 [6] - The company received a warning letter from the China Securities Regulatory Commission in June due to improper management of raised funds [6]